Bioactive Lipid Mediators Core (BLMC)

生物活性脂质介体核心（BLMC）旨在支持附属科学家正在进行的工作 旨在了解长期使用药物对脂质信号传导的系统和神经生理学结果。 对脂质生物标志物的关注针对一个新兴领域，该领域具有独特的前景，可以添加一个新的框架 为了理解脂质信号如何在广泛的组织中（例如，血浆、CNS、肝脏、母乳） 与药物使用的发展和维持相关的稳态失调有关 紊乱布拉德肖实验室开发了脂质提取和分析技术，专门针对 小分子脂质代谢物，如内源性大麻素、脂胺、三尖杉酯碱、白三烯， 消退素。这些类型的脂质已被证明是改变的反应暴露于滥用药物 了解这种调节有可能提供独特的见解， 药物使用会引起全身和中枢神经系统的变化。这种理解将推动 发现治疗毒瘾的新疗法。我们将通过1）血浆评价 多种药物滥用模型中的脂质组学模式。使用药物使用的动物模型（THC，阿片类药物，酒精） 我们将使用我们优化的分析技术来分析生物活性脂质代谢物信号分子， 以确定急性和慢性药物暴露如何引起这些脂质的全身变化 班然后，这种分析技术将用于确定内源性大麻素和相关的 脂质信号分子在人类不同疾病状态（创伤后应激障碍、脑震荡、药物成瘾）中的变化 等离子体2)慢性药物滥用患者中枢神经系统靶区生物活性脂质的性别差异分析 作为遗传性别的函数。这将提供一个新的框架，以评估跨 以及毒品模特和性之间的关系3)母乳中生物活性脂质变化的鉴定 接触滥用药物（THC，阿片类药物）。啮齿类药物使用模型中母乳的脂质组学分析 (THC阿片类药物）将更清楚地了解这些药物的存在如何改变脂质 这可能会对后代的健康产生长期影响。4)开发数据 生物活性脂质代谢物的科学分析技术，以推动药物滥用的新假设 引起全身和CNS脂质信号传导的变化。结合日益强大的分析能力， 内部开发的新数据挖掘和聚类分析技术将为该领域提供新的 用于解释脂质代谢组学信息的工具。5)增加代表性不足的少数族裔的管道 (URM)学生的职业生涯在干重点是lipidomic质谱技术。在 与IU的少数民族服务计划合作，URM学生将提供独特的机会， 培训和研究是针对脂质组学和质谱领域以及多个 专业发展的机会。

The Bioactive Lipid Mediators Core (BLMC) is designed to support the ongoing work of affiliated scientists aiming to understand the systemic and neurophysiological outcomes of chronic drug use on lipid signaling. The focus on lipid biomarkers targets an emerging field that has unique promise to add a novel framework for understanding how lipid signaling in a wide range of tissues (e.g., plasma, CNS, liver, breast milk) is related to homeostatic dysregulation associated with the development and maintenance of drug use disorders. The Bradshaw lab has developed lipid extraction and analytical techniques aimed specifically at small molecule lipid metabolites like the endocannabinoids, lipoamines, prostaglandins, leukotrienes, and resolvins. These classes of lipids of have been shown to change in response to exposure to drugs of abuse and understanding this regulation has the potential to provide unique insight into how both acute and chronic drug use drives both systemic and central nervous system changes. This understanding would then drive the discovery of novel therapies to treat drug addiction. We will accomplish this by 1) Evaluation of plasma lipidomics patterns in multiple drug abuse models. Using animal models of drug use (THC, opioids, alcohol) we will use our optimized analytical techniques for analysis of bioactive lipid metabolite signaling molecules in plasma to determine how acute and chronic drug exposure causes systemic changes in these lipid classes. This analysis technique will then be used to determine how endogenous cannabinoid and related lipid signaling molecules changes in different disease states (PTSD, concussion, drug addiction) in human plasma. 2) Analyze sex difference in bioactive lipids in in targeted areas of the CNS with chronic drug use as a function of genetic sex. This will provide a novel framework to evaluate unique characteristics across and between drug models and sex. 3) Identification of changes in bioactive lipids in breast milk with exposure to drugs of abuse (THC, opioids). Lipidomics analysis of breastmilk in rodent models of drug use (THC, opioids) will provide a clearer understanding on how the presence of these drugs changes the lipid profile of breastmilk in a way that may have long term health consequences for offspring. 4) Develop data science analytical techniques of bioactive lipid metabolites to drive novel hypotheses on how drugs of abuse cause changes in systemic and CNS lipid signaling. Coupling the power of increasingly powerful analytical techniques with novel data mining and cluster analyses developed in-house will provide the field with new tools for interpreting lipid metabolomic information. 5) Increase the pipeline for underrepresented minority (URM) students for careers in STEM with a focus on lipidomic mass spectrometric techniques. In partnership with minority serving programs at IU, URM students will be provided unique opportunities for training and research that are tailored to the field of lipidomics and mass spectrometry as well as multiple programmatic opportunities for professional development.